“Key milestone”: Chr. Hansen trial finds probiotic potential for painkiller gut damage defense

636620528615696689gut belly.jpg

16 May 2018 --- A Chr. Hansen clinical trial has demonstrated the effectiveness of probiotic strains in protecting against potential gut damage caused by the regular use of household painkillers. Chr. Hansen state that they will now focus on fully exploiting the strains full potential, deepening understanding of the underlying mechanisms and gathering sufficient data to publish in a scientific journal. The findings add to a growing research area using probiotics for health.

“This study further confirms the potential of probiotics in bringing benefits beyond well-studied areas in gastro-intestinal (GI) health and well-being. In that context, it is in line with our expectation that probiotics and beneficial bacteria from the microbiome will be of increasing relevance for the maintenance of health and the prevention and treatment of disease.” Johan van Hylckama Vlieg, Vice President of Microbiome & Human Health Innovation tells NutritionInsight.

“The clinical trial identified that participants taking the probiotic experienced a significant defense against GI damage caused by a widely used household painkiller compared to those who took the placebo. This indicates a clear protective effect from the strain – both regarding the reduction of intestinal damage and the number of ulcers caused.” 

The clinical trial used capsule endoscopy to reveal GI damage. It’s one of the first times that this advanced technology was used in a probiotic intervention trial.

Common GI side effects from household painkiller
The household painkiller is an NSAID (non-steroidal anti-inflammatory drugs), which are some of the most widely used pharmaceuticals in the world, according to Chr. Hansen. More than 50 million adults in the US take such drugs regularly. Chronic, low-dose use of the NSAID ASA is recommended for its cardiovascular-protecting properties and is today prescribed to 80 percent of those with an elevated cardiovascular risk profile in the US. 

However, Chr. Hansen adds that the regular use of NSAIDs can have side effects. ASA has emerged as one of the causes of ulcer bleeding in developed countries over the last two decades, underscoring an arguably unmet need to protect the gastrointestinal against damage caused by long-term and chronic NSAID therapy.

Probiotic innovation programme 
The clinical trial has been coined a “key milestone” in Chr. Hansen’s probiotic innovation program. One of the focus areas of the innovation program is to prove the potential of probiotic strains to protect against intestinal damage and develop these into proprietary products. 

“With this clinical data, we are breaking ground into a new field. As part of our Nature’s no.1 strategy, we work to unleash the potential of probiotics as a safe and effective solution into new health areas. To do this, we focus on careful strain selection, high-quality clinical trial design and professional execution”, explains van Hylckama Vlieg.

“Multiple paths for real-world implications can be envisioned, and today we are evaluating the different options. We are also currently performing additional scientific analyses in order to maximize the potential of our findings.” 

“However, we are still at the early scientific discovery stages and have not concluded on the final product concept yet,” he adds.

“With this particular strain, we have reached a key milestone. We are now continuing to invest in this concept to further investigate the potential of the strain. Our goal is to make it available to the many millions who need to take ASA regularly to support their long-term health,” concludes van Hylckama Vlieg.

The research builds on recent developments from Chr. Hansen regarding the use of probiotics strains in medical treatment. Last month, the company announced a partnership with Prota Therapeutics, developer of oral immunotherapies to treat food allergies. The partnership seeks to utilize Chr. Hansen’s probiotic strain, Lactobacillus rhamnosus (LGG) in the treatment of peanut allergies.

“Chr. Hansen has demonstrated the capability to deliver a pharmaceutical quality product that can be regulated as a biological therapeutic product. Together with our proprietary peanut protein formulation, we aim to progress this through to commercialization of a treatment for peanut allergies,” says Dr. Suzanne Lipe, CEO at Prota Therapeutics.

Regarding the medicines hitting the shelves, Thomas Gundelund Rasmussen, Director, Human Health and Microbiome Innovation told NutritionInsight at the time: “It will be approximately three years for the phase three clinical study, which is followed by discussions with the US FDA. After which, Prota intends to submit a Biologics License Application to FDA.”

By Laxmi Haigh

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Weekly Digest: Arla expands fiber yogurt range, probiotics may reduce hay fever symptoms

25 May 2018 --- This week in nutrition news, Arla revealed a new addition to its fiber yogurt range, hoping to boost the UK's daily fiber intake. In research news, probiotic formulations were found to have positive effects on hay fever symptoms, while following a diet high in antioxidants may protect people from the adverse effects of pollution. Furthermore, researchers have made steps in understanding the link between a mothers nutrition during pregnancy and the child's growth, and a study undercovered that consumers are more likely to order unhealthy options when dining out amid louder, ambient music.

Nutrition & Health News

DuPont's probiotic reach expands with Brazilian recognition of health claim

25 May 2018 --- DuPont Nutrition & Health Science has earned approval from the Brazilian Health Regulatory Agency (ANVISA) for its Bifidobacterium lactis HN019 probiotic strain. The regulatory green light marks the recognition of the science behind the strain and allows an on-pack health claim. Customers in Brazil can now bring new probiotic products and dietary supplements faster to market using the first DuPont probiotic to qualify for an approved health claim on the local market.

Nutrition & Health News

Microbiome solutions: A key theme at Vitafoods Europe 2018

24 May 2018 --- Research into the microbiome – the aggregated microbial species in our body – is gaining increasing attention and investment. Although the term is often associated with digestive health, the body, in fact, contains multiple microbiome. This is currently spurring on research and innovation in areas as wide-ranging as women’s health, weight management, immunity and skin health. At Vitafoods Europe 2018, NutritionInsight spoke with suppliers about their efforts and innovations in the microbiome space, using pre or probiotics for gut health and beyond.

Nutrition & Health News

Key gut-brain interplays identified, enhancing possibilities for neurological treatments

21 May 2018 --- Steps have been taken toward untangling the complex interplay that allows the byproducts of microorganisms living in the gut to influence the progression of neurodegenerative diseases. Researchers have defined a pathway between the two, coined the gut-brain axis, that may help guide therapies for multiple sclerosis and other neurological diseases. Essentially, some gut microbes were found to activate an anti-inflammatory pathway that can limit neurodegeneration.

Nutrition & Health News

Sports nutrition mainstreams: A key theme at Vitafoods Europe 2018

18 May 2018 --- Boundaries are blurring as sports nutrition continues to move mainstream. Ingredients and products aimed at promoting active living were a clear standout theme at Vitafoods Europe this year. New launches targeted a wide scope of aspects related to active lifestyles, and are likely to resonate not just with hardcore athletes but also with consumers of different ages and activity groups. 

More Articles
URL : http://www.nutritioninsight.com:80/news/chr-hansen-trial-finds-probiotics-potential-in-protection-against-gut-damage-from-medication.html